Legal & General Group Plc Boosts Stake in Indivior PLC $INDV

Legal & General Group Plc raised its position in Indivior PLC (NASDAQ:INDV) by 127.0% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 307,650 shares of the company’s stock after purchasing an additional 172,129 shares during the period. Legal & General Group Plc’s holdings in Indivior were worth $10,755,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in INDV. Quarry LP purchased a new stake in Indivior in the 3rd quarter valued at about $26,000. Raymond James Financial Inc. purchased a new stake in Indivior in the 2nd quarter valued at about $26,000. Salomon & Ludwin LLC purchased a new stake in Indivior in the 4th quarter valued at about $30,000. Harbor Capital Advisors Inc. increased its stake in Indivior by 309.9% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock valued at $37,000 after buying an additional 781 shares during the last quarter. Finally, GAMMA Investing LLC increased its stake in shares of Indivior by 544.6% during the 4th quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock worth $43,000 after purchasing an additional 1,013 shares during the last quarter. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Insiders Place Their Bets

In other Indivior news, Director Stuart A. Kingsley acquired 940 shares of Indivior stock in a transaction that occurred on Friday, March 6th. The stock was acquired at an average cost of $31.86 per share, for a total transaction of $29,948.40. Following the purchase, the director owned 5,582 shares of the company’s stock, valued at approximately $177,842.52. This represents a 20.25% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.74% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on INDV shares. Weiss Ratings lowered shares of Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 16th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $39.33.

Indivior Trading Up 5.1%

Indivior stock opened at $35.43 on Thursday. Indivior PLC has a 1-year low of $12.81 and a 1-year high of $41.00. The firm has a market capitalization of $4.32 billion, a price-to-earnings ratio of 18.17 and a beta of 0.88. The firm has a 50 day simple moving average of $34.29 and a 200 day simple moving average of $34.02.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.96 earnings per share for the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. The business had revenue of $317.00 million during the quarter. On average, equities research analysts forecast that Indivior PLC will post 4.05 EPS for the current year.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.